Effects of two peroxisome proliferators (ciprofibrate and fenofibrate) on peroxisomal membrane proteins and dihydroxyacetone-phosphate acyl-transferase activity in rat liver.

Cell Mol Biol (Noisy-le-grand)

Laboratoire de Biologie Moléculaire et Cellulaire, Faculté des Sciences Mirande, Université de Bourgogne, Dijon, France.

Published: February 1993

The effects of ciprofibrate and fenofibrate, which are more potent peroxisome proliferators than clofibrate, on the activities of dihydroxyacetone-phosphate acyl-transferase (DHAP-AT) and glycerol-3-phosphate acyl-transferase (G3P-AT) were studied at the two pH optima 5.5 and 7.4 in subcellular fractions of rat liver, and in solubilized peroxisomal membranes (PMP) as well. Protein was also analyzed by gel electrophoresis. 1) Under the conditions of the specific activity of peroxisomal acyl-CoA oxidase (CN(-)-ACO) being increased (8 to 9-fold), there was no specific induction of the DHAP-AT activity when measured at pH 5.5 in purified peroxisomes and PMP. However, the total activities of DHAP-AT in these two fractions were increased by 6 to 11 times, as a result of hepatomegaly and peroxisome proliferation. In contrast, they were only slightly enhanced (x 1.1 to 2.2-fold) when determined at pH 7.4. The magnitude of the effects of a fibrate treatment was, therefore, dependent on the pH of the incubation medium. 2) Experiments of reversibility of enzyme induction reinforced the finding that the peroxisomal DHAP-AT activity is not specifically induced by ciprofibrate and fenofibrate. 3) Our results suggest the existence of a peroxisomal G3P-AT, non-inducible by fibrates, in the rat liver. 4) Induction of peroxisomal membrane-associated polypeptides with apparent molecular masses of 26- and 36-kDa was evidenced in stained electrophoretic gels of protein.

Download full-text PDF

Source

Publication Analysis

Top Keywords

ciprofibrate fenofibrate
12
rat liver
12
peroxisome proliferators
8
dihydroxyacetone-phosphate acyl-transferase
8
dhap-at activity
8
peroxisomal
6
effects peroxisome
4
proliferators ciprofibrate
4
fenofibrate peroxisomal
4
peroxisomal membrane
4

Similar Publications

Article Synopsis
  • This study focuses on primary biliary cholangitis (PBC) in non-white populations, specifically analyzing Brazilian patients to assess their clinical features and treatment outcomes.
  • The research included 562 predominantly female patients, revealing that after an average follow-up of 6.2 years, a significant portion experienced advanced liver disease, and most were treated with ursodeoxycholic acid (UDCA), with some requiring additional treatments.
  • Findings indicate that while PBC features in Brazilian patients are similar to those in Caucasian and Asian populations, the response to UDCA therapy was lower than expected and varied widely, highlighting the need for standardization in treatment evaluation.
View Article and Find Full Text PDF

Alleviation of Toxicity Caused by Overactivation of Pparα through Pparα-Inducible miR-181a2.

Mol Ther Nucleic Acids

December 2017

College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China; Bio-medical Center, Huazhong Agricultural University, Wuhan 430070, China. Electronic address:

Widely varied compounds, including certain plasticizers, hypolipidemic drugs (e.g., ciprofibrate, fenofibrate, WY-14643, and clofibrate), agrochemicals, and environmental pollutants, are peroxisome proliferators (PPs).

View Article and Find Full Text PDF

Introduction: Several studies have investigated the occurrence of venous thromboembolic events (phlebitis and pulmonary embolism) [VTE] and fibrates. Fibrates could be associated with VTE although published data are contradictory. The objective of this study is to confirm the link between VTE and fibrates.

View Article and Find Full Text PDF

Clofibric acid derivatives called fibrates, are quite commonly used lipid-lowering drugs, so it is necessary to know beneficial and adverse effects of these compounds on the body. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that benefits of four fibrates such as: bezafibrate, ciprofibrate, fenofibrate and gemfibrozil continue outweigh their risk in treatment of people with blood lipid disorders. According to recommendations of the CHMP fibrates should not be used as first-line drugs, except in patients with severe hypertriglyceridemia and patients who cannot use statins.

View Article and Find Full Text PDF

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. Three subtypes, PPARα, PPARβ/δ, and PPARγ, have been identified so far. PPARα is expressed in the liver, kidney, small intestine, heart, and muscle, where it activates the fatty acid catabolism and control lipoprotein assembly in response to long-chain unsaturated fatty acids, eicosanoids, and hypolipidemic drugs (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!